Imatinib, the first Abl‐specific tyrosine kinase inhibitor (TKI), competitively binds to its enzymatic activity pocket, has been developed for Ph+ leukemia treatment, and is considered a milestone in targeted cancer therapy.[6] However, during clinical application, large numbers of imatinib‐resistant Ph+ leukemia cases have been discovered and reported. The gene discussed is ABL1; the disease is cancer.